Arcus Biosciences Outperform
Most Popular
A top banking lawyer who just joined Blackstone's board is moving to the powerhouse...
Reginald Brown, a top financial regulatory lawyer, and three of his partners are leaving WilmerHale for Kirkland Ellis. Kirkland ...
Al Sharpton: President Trump 'and his cronies' will pay for their 'many crimes.' But...
During the "Gotcha!" portion of his MSNBC program Sunday, Al Sharpton went to work on President Donald Trump, going over a lengthy list of folks the president may pardon soon following his pre-Thanksgiving pardon of former national security adviser Mike Flynn.Who could be next? Paul Manafort? Rick Gates? Steve Bannon? Elliott Brody? Trump himself?Sharpton then said "the villains in the Trump administration cannot be granted a total reprieve with the presidential pardon because the president of the United States can only pardon federal crimes. He has absolutely no power over state charges, and nearly everyone in the Trump orbit is facing state-level liability."He added that Trump "and his adult children are facing multiple tax fraud cases. His son-in-law, Jared Kushner, is under investigation for falsifying real estate documents, and Paul Manafort could see a revival of state charges, just to make a few. And none of those can be disappeared with the presidential pardon. The president and his cronies will be held accountable for their many crimes. The turkeys have come home to roost. And I gotcha." [embed]https://youtube.com/watch?v=gt_1kTlNyos&rel=0[/embed] POLITICS NATION WITH REV AL GOTCHA RE tRump TURKEY 11 29 2020 youtu.be What about Sharpton?It's one
Stocks tumble at end of record-setting month on Wall Street
US stocks tumbled Monday as investors closed out a record-setting month by locking in some profits. The Dow Jones industrial average slid as much as 446.73 points, or about 1.5 percent, to 29,463.64 but was still on pace for its biggest monthly gain since 1987 after crossing the 30,000 mark last week. The blue-chip index had surged 2,962 points in November, or some 11 percent, even at Monday’s intraday low, helped by strides toward a coronavirus vaccine and Joe Biden’s presidential election victory. The S&P 500 was on track to end the month with a more than 11 percent gain — its largest for any November ever — despite dropping as much as 1.2 percent Monday. The tech-heavy Nasdaq also slid as much as 1.5 percent after touching a new intraday record of 12,244.65 in early trading. “We’ve had such a run here in short order and I just think people are saying, ‘OK, dump a little bit of my big winners and if it does pull back here at some point, I’ll probably go in after it again,'” Jim Paulsen, chief investment strategist at the Leuthold Group, told The Post. Wall Street’s major indexes ironically soared to record highs
Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell...
Genprex, Inc. ("Genprex” or the "Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is pleased to announce it has commenced clinical trial site recruitment for its upcoming Acclaim-1 clinical trial for the treatment of non-small cell lung cancer (NSCLC). As planned, the timing of the patient recruitment and enrollment puts the Company on track for its Acclaim-1 clinical trial to commence in the first-half of 2021. Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines Genprex’s lead drug candidate, REQORSA™ immunogene therapy with AstraZeneca PLC’s Tagrisso in patients with late stage NSCLC with mutated epidermal growth factor receptors (EGFRs), whose disease progressed after treatment with Tagrisso. Genprex received U.S. Food and Drug Administration (FDA) Fast Track Designation for its Acclaim-1 patient population in January of 2020. "Our clinical team is engaging with prestigious cancer centers and research institutions across the U.S. to ensure we select optimal study sites, which play an important role in the success of a clinical trial,” said Rodney Varner, President and Chief Executive Officer of Genprex. "We look forward to working with leading clinical investigators who will help drive our mission
Bitcoin surges to all-time high as it nears $20,000
The price of Bitcoin hit a new all-time high on Monday as investors increasingly scoop up risky assets amid the topsy-turvy pandemic economy. The controversial cryptocurrency’s value hit an all-time peak of $19,864.15, shattering its previous high-water mark of $19,783.21 which was set back in December 2017. It was recently up 6.1 percent at $19,306.35. Bitcoin has gained more than 170 percent this year, with most of that growth coming since September. Investors cite demand for riskier assets amid unprecedented fiscal and monetary stimulus, hunger for assets perceived as resistant to inflation, and expectations that cryptocurrencies will win mainstream acceptance as payment companies including PayPal and Square have recently allowed their use. “Bitcoin is a natural safe haven for those seeking shelter from rapidly increasing central bank money printing and the inflation that everyone agrees is already increasing,” said Sergey Nazarov, co-founder of Chainlink, a decentralized network that provides data to smart contracts on the blockchain. This most recent crypto craze is benefiting from an unprecedented, pandemic-marred market reality in which stocks are trading at nosebleed prices while bond yields are hovering around zero. That combination, experts say, has created a whole new class of crypto investor that is viewing
